Pharmatest has announced an upcoming seminar at the Boston Marriott hotel in Copley Place.
Titled ‘Significance of Bone Metastases and Targeting Tumor, Bone and Immune System’, the seminar will take place on 6 September from 8.00 am to 10.30 am.
Many oncology drugs still fail in clinical trials due to poor efficacy. One important reason for this is that compound efficacy is not confirmed in clinically relevant preclinical metastasis models before entering clinical trials. This would be important because the metastatic microenvironment changes tumour properties and induces drug resistance.
This educational seminar highlights significance of bone metastases in clinical and preclinical aspects. Keynote speaker of the seminar will be Dr. Matthew Smith from Massachusetts General Hospital Cancer Center, and other speakers will be from MassBio, Taconic Biosciences, and Pharmatest.
CEO of Pharmatest Jussi Halleen comments: "It is our mission to decrease the currently very high failure rates of oncology drugs in clinical trials, and we want to emphasise the importance of confirming compound efficacy in preclinical metastasis models to achieve this goal".
Pharmatest welcomes everyone to join this educational seminar. The company offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology Pharmatest has been the leading provider of bone metastasis models since 2005.